Business & Industry
Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351
Japan-based Chugai Pharmaceutical has entered into an exclusive license agreement with British pharmaceutical company GlaxoSmithKline (GSK) for the anti-dengue virus antibody known as AID351, in a move that advances global efforts to combat one of the world's most widespread...
BioPharma
Lonza Launches Rapid Media Prototyping Service to Accelerate Biopharmaceutical Development
Lonza has announced the launch of its Rapid Media Prototyping Service (RaMP) — a solution designed to give biopharmaceutical companies faster access to custom liquid and powder media for screening, process confirmation, and early development.
Delivering Speed and Flexibility in...
BioPharma
Sandoz Expands Global Pipeline with Multi-Product Biosimilar Agreement
Sandoz has entered into a collaboration agreement with Shanghai Henlius Biotech to co-develop a series of new biosimilars across international markets. The milestone-based transaction carries a total consideration of up to $322m, including near-term payments of up to $100.5m...
Business & Industry
Axtria Scales Forward Deployed Engineering Team to 1,000 Experts
Global data analytics provider Axtria Inc. announced plans on August 13, 2026, to expand its Forward Deployed Engineering organization to 1,000 engineers by December 2026. This expansion creates the industry’s largest pharma AI engineering initiative, addressing growing customer demand...
Business & Industry
FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement
Following months of negotiations with industry stakeholders, the US Food and Drug Administration (FDA) has published its proposed commitment letter for the GDUFA IV program. Announced in the Federal Register on Monday alongside details for an upcoming public meeting,...
News
Buying Guide: How to Source High-Quality Selank for Research
Peptide research continues to expand across academic and independent laboratory settings, and with that growth comes an increasing need for reliable sourcing practices. Selank, a synthetic peptide studied in neuroscience and behavioral research contexts, is one of many compounds...
BioPharma
CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture
CSPC Pharmaceutical and AstraZeneca have signed a joint venture contract to establish a new-generation production facility in Shijiazhuang, China. The collaboration focuses on the manufacturing and global supply of mutually agreed biologics drug substances, with capital contributions structured at...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read